Venus Remedies Limited has informed the Exchange regarding Outcome of Board Meeting held on May 26, 2026.

Dividend Yield Above 3pctCorporate Actions View source PDF

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+10.3%1-day move

₹1160.00

prior close

₹1219.10

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+0.0+0.0+0.0+10.3+15.9+21.7+27.7+34.1+41.9+48.5+66.3+35.6—

Up moveDown movePending

AI summary

Venus Remedies Limited reported strong audited financial results for FY 2025-26. Standalone net profit surged 89% to Rs. 99.31 crore from Rs. 52.55 crore, while consolidated net profit jumped 127% to Rs. 102.78 crore. Revenue from operations grew 19% to Rs. 768.73 crore standalone. The board recommended a final dividend of Rs. 10 per share (100% on face value Rs. 10), with record date set for August 7, 2026. The 37th AGM is scheduled for August 20, 2026. Key appointments include Mr. Saransh Chaudhary as Managing Director and reappointment of independent directors. The company also adopted new MOA and AOA to align with Companies Act 2013.

Likely market impact

Strong profit growth of 89-127% year-on-year with a 100% dividend payout signals healthy financial performance and shareholder-friendly policies, which could positively influence investor sentiment.